Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | COVID-19 | Research

Clinical clustering with prognostic implications in Japanese COVID-19 patients: report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics

Authors: Shiro Otake, Shotaro Chubachi, Ho Namkoong, Kensuke Nakagawara, Hiromu Tanaka, Ho Lee, Atsuho Morita, Takahiro Fukushima, Mayuko Watase, Tatsuya Kusumoto, Katsunori Masaki, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Norihiro Harada, Tetsuya Ueda, Soichiro Ueda, Takashi Ishiguro, Ken Arimura, Fukuki Saito, Takashi Yoshiyama, Yasushi Nakano, Yoshikazu Mutoh, Yusuke Suzuki, Koji Murakami, Yukinori Okada, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, The Japan COVID-19 Task Force

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

The clinical course of coronavirus disease (COVID-19) is diverse, and the usefulness of phenotyping in predicting the severity or prognosis of the disease has been demonstrated overseas. This study aimed to investigate clinically meaningful phenotypes in Japanese COVID-19 patients using cluster analysis.

Methods

From April 2020 to May 2021, data from inpatients aged ≥ 18 years diagnosed with COVID-19 and who agreed to participate in the study were collected. A total of 1322 Japanese patients were included. Hierarchical cluster analysis was performed using variables reported to be associated with COVID-19 severity or prognosis, namely, age, sex, obesity, smoking history, hypertension, diabetes mellitus, malignancy, chronic obstructive pulmonary disease, hyperuricemia, cardiovascular disease, chronic liver disease, and chronic kidney disease.

Results

Participants were divided into four clusters: Cluster 1, young healthy (n = 266, 20.1%); Cluster 2, middle-aged (n = 245, 18.5%); Cluster 3, middle-aged obese (n = 435, 32.9%); and Cluster 4, elderly (n = 376, 28.4%). In Clusters 3 and 4, sore throat, dysosmia, and dysgeusia tended to be less frequent, while shortness of breath was more frequent. Serum lactate dehydrogenase, ferritin, KL-6, d-dimer, and C-reactive protein levels tended to be higher in Clusters 3 and 4. Although Cluster 3 had a similar age as Cluster 2, it tended to have poorer outcomes. Both Clusters 3 and 4 tended to exhibit higher rates of oxygen supplementation, intensive care unit admission, and mechanical ventilation, but the mortality rate tended to be lower in Cluster 3.

Conclusions

We have successfully performed the first phenotyping of COVID-19 patients in Japan, which is clinically useful in predicting important outcomes, despite the simplicity of the cluster analysis method that does not use complex variables.
Literature
1.
go back to reference Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375.PubMedPubMedCentralCrossRef Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375.PubMedPubMedCentralCrossRef
2.
go back to reference Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.PubMedCrossRef Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.PubMedCrossRef
3.
go back to reference Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021;84(1):3–8.PubMedCrossRef Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021;84(1):3–8.PubMedCrossRef
5.
go back to reference Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care. 2019;25:489–97.PubMedCrossRef Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care. 2019;25:489–97.PubMedCrossRef
6.
go back to reference Rubio-Rivas M, Corbella X, Mora-Luján JM, Loureiro-Amigo J, López Sampalo A, Yera Bergua C, et al. Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19. J Clin Med. 2020;9:3488.PubMedCentralCrossRef Rubio-Rivas M, Corbella X, Mora-Luján JM, Loureiro-Amigo J, López Sampalo A, Yera Bergua C, et al. Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19. J Clin Med. 2020;9:3488.PubMedCentralCrossRef
7.
go back to reference Ye W, Lu W, Tang Y, Chen G, Li X, Ji C, et al. Identification of COVID-19 clinical phenotypes by principal component analysis-based cluster analysis. Front Med (Lausanne). 2020;7:570614.CrossRef Ye W, Lu W, Tang Y, Chen G, Li X, Ji C, et al. Identification of COVID-19 clinical phenotypes by principal component analysis-based cluster analysis. Front Med (Lausanne). 2020;7:570614.CrossRef
8.
go back to reference Lusczek ER, Ingraham NE, Karam BS, Proper J, Siegel L, Helgeson ES, et al. Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. PLoS ONE. 2021;16:e0248956.PubMedPubMedCentralCrossRef Lusczek ER, Ingraham NE, Karam BS, Proper J, Siegel L, Helgeson ES, et al. Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. PLoS ONE. 2021;16:e0248956.PubMedPubMedCentralCrossRef
9.
go back to reference Dupont T, Caillat-Zucman S, Fremeaux-Bacchi V, Morin F, Lengliné E, Darmon M, et al. Identification of distinct immunophenotypes in critically ill coronavirus disease 2019 patients. Chest. 2021;159:1884–93.PubMedCrossRef Dupont T, Caillat-Zucman S, Fremeaux-Bacchi V, Morin F, Lengliné E, Darmon M, et al. Identification of distinct immunophenotypes in critically ill coronavirus disease 2019 patients. Chest. 2021;159:1884–93.PubMedCrossRef
10.
go back to reference Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, et al. Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest. 2021;160:929–43.PubMedCrossRef Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, et al. Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest. 2021;160:929–43.PubMedCrossRef
11.
go back to reference Reddy K, Sinha P, O’Kane CM, Gordon AC, Calfee CS, McAuley DF. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020;8:631–43.PubMedCrossRef Reddy K, Sinha P, O’Kane CM, Gordon AC, Calfee CS, McAuley DF. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020;8:631–43.PubMedCrossRef
12.
go back to reference Ishii M, Terai H, Kabata H, Masaki K, Chubachi S, Tateno H, et al. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: a multicenter retrospective study. J Infect. 2020;81:e3-5.PubMedPubMedCentralCrossRef Ishii M, Terai H, Kabata H, Masaki K, Chubachi S, Tateno H, et al. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: a multicenter retrospective study. J Infect. 2020;81:e3-5.PubMedPubMedCentralCrossRef
13.
go back to reference Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.PubMedPubMedCentralCrossRef Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.PubMedPubMedCentralCrossRef
15.
go back to reference Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020;73:e3677–89.PubMedCentralCrossRef Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020;73:e3677–89.PubMedCentralCrossRef
16.
go back to reference Namkoong H. Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan. medRxiv. 2021. Namkoong H. Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan. medRxiv. 2021.
17.
go back to reference Tanaka H, Namkoong H, Lee H, Morita A, Chubachi S, Kabata H, et al. Clinical characteristics of patients with coronavirus disease (COVID-19): preliminary baseline report of Japan COVID-19 task force, a nation-wide consortium to investigate host genetics of COVID-19. Int J Infect Dis. 2021;113:74–81.PubMedPubMedCentralCrossRef Tanaka H, Namkoong H, Lee H, Morita A, Chubachi S, Kabata H, et al. Clinical characteristics of patients with coronavirus disease (COVID-19): preliminary baseline report of Japan COVID-19 task force, a nation-wide consortium to investigate host genetics of COVID-19. Int J Infect Dis. 2021;113:74–81.PubMedPubMedCentralCrossRef
19.
go back to reference Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16-25.PubMedPubMedCentralCrossRef Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16-25.PubMedPubMedCentralCrossRef
20.
go back to reference Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021;37:e3377.PubMed Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021;37:e3377.PubMed
21.
go back to reference Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–8.PubMedPubMedCentralCrossRef Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–8.PubMedPubMedCentralCrossRef
22.
go back to reference Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303–10.PubMedPubMedCentralCrossRef Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303–10.PubMedPubMedCentralCrossRef
23.
go back to reference Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.PubMedPubMedCentralCrossRef Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.PubMedPubMedCentralCrossRef
24.
go back to reference Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92:1915–21.PubMedPubMedCentralCrossRef Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92:1915–21.PubMedPubMedCentralCrossRef
25.
go back to reference Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14:612–20.PubMedCrossRef Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14:612–20.PubMedCrossRef
26.
go back to reference McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res. 1992;1:27–48.PubMedCrossRef McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res. 1992;1:27–48.PubMedCrossRef
27.
go back to reference Ye W, Robbins RT. Cluster analysis of longidorus species (nematoda: longidoridae), a new approach in species identification. J Nematol. 2004;36:207–19.PubMedPubMedCentral Ye W, Robbins RT. Cluster analysis of longidorus species (nematoda: longidoridae), a new approach in species identification. J Nematol. 2004;36:207–19.PubMedPubMedCentral
28.
go back to reference Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125:481–3.PubMedPubMedCentralCrossRef Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125:481–3.PubMedPubMedCentralCrossRef
29.
go back to reference Porta-Etessam J, Núñez-Gil IJ, González García N, Fernandez-Perez C, Viana-Llamas MC, Eid CM, et al. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection. 2021;49:677–84.PubMedPubMedCentralCrossRef Porta-Etessam J, Núñez-Gil IJ, González García N, Fernandez-Perez C, Viana-Llamas MC, Eid CM, et al. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection. 2021;49:677–84.PubMedPubMedCentralCrossRef
30.
go back to reference Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180:1081–9.PubMedCrossRef Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180:1081–9.PubMedCrossRef
31.
go back to reference Sobhani S, Aryan R, Kalantari E, Soltani S, Malek N, Pirzadeh P, et al. Association between clinical characteristics and laboratory findings with outcome of hospitalized COVID-19 patients: a report from Northeast Iran. Interdiscip Perspect Infect Dis. 2021;2021:5552138.PubMedPubMedCentralCrossRef Sobhani S, Aryan R, Kalantari E, Soltani S, Malek N, Pirzadeh P, et al. Association between clinical characteristics and laboratory findings with outcome of hospitalized COVID-19 patients: a report from Northeast Iran. Interdiscip Perspect Infect Dis. 2021;2021:5552138.PubMedPubMedCentralCrossRef
32.
go back to reference Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7:e671–8.PubMedPubMedCentralCrossRef Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7:e671–8.PubMedPubMedCentralCrossRef
33.
go back to reference Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.PubMedPubMedCentralCrossRef Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.PubMedPubMedCentralCrossRef
34.
go back to reference Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43.PubMedCrossRef Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43.PubMedCrossRef
35.
go back to reference Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.PubMedPubMedCentralCrossRef Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.PubMedPubMedCentralCrossRef
36.
go back to reference Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21:167–79.PubMedCrossRef Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21:167–79.PubMedCrossRef
37.
go back to reference DeMerle K, Angus DC, Seymour CW. Precision medicine for COVID-19: phenotype anarchy or promise realized? JAMA. 2021;325:2041–2.PubMedCrossRef DeMerle K, Angus DC, Seymour CW. Precision medicine for COVID-19: phenotype anarchy or promise realized? JAMA. 2021;325:2041–2.PubMedCrossRef
38.
go back to reference Chauhan K, Pattharanitima P, Piani F, Johnson RJ, Uribarri J, Chan L, et al. Prevalence and outcomes associated with hyperuricemia in hospitalized patients with COVID-19. Am J Nephrol. 2022;53:78–86.PubMedCrossRef Chauhan K, Pattharanitima P, Piani F, Johnson RJ, Uribarri J, Chan L, et al. Prevalence and outcomes associated with hyperuricemia in hospitalized patients with COVID-19. Am J Nephrol. 2022;53:78–86.PubMedCrossRef
39.
go back to reference Deniz C, Selçuk Y, Kubilay I, Ahmed CG, Didar S, Ahmed BG, et al. Uric acid and mortality relationship in covid-19. Acta Medica Mediterranea. 2022;38(1):725–31. Deniz C, Selçuk Y, Kubilay I, Ahmed CG, Didar S, Ahmed BG, et al. Uric acid and mortality relationship in covid-19. Acta Medica Mediterranea. 2022;38(1):725–31.
40.
go back to reference Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25:210–6.PubMedCrossRef Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25:210–6.PubMedCrossRef
41.
go back to reference Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018;8:4314.PubMedPubMedCentralCrossRef Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018;8:4314.PubMedPubMedCentralCrossRef
42.
go back to reference Ripabelli G, Sammarco ML, Cannizzaro F, Montanaro C, Ponzio GV, Tamburro M. A coronavirus outbreak linked to a funeral among a Romani community in Central Italy. Front Med (Lausanne). 2021;8:617264.CrossRef Ripabelli G, Sammarco ML, Cannizzaro F, Montanaro C, Ponzio GV, Tamburro M. A coronavirus outbreak linked to a funeral among a Romani community in Central Italy. Front Med (Lausanne). 2021;8:617264.CrossRef
43.
go back to reference Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13362.PubMedCrossRef Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13362.PubMedCrossRef
45.
Metadata
Title
Clinical clustering with prognostic implications in Japanese COVID-19 patients: report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics
Authors
Shiro Otake
Shotaro Chubachi
Ho Namkoong
Kensuke Nakagawara
Hiromu Tanaka
Ho Lee
Atsuho Morita
Takahiro Fukushima
Mayuko Watase
Tatsuya Kusumoto
Katsunori Masaki
Hirofumi Kamata
Makoto Ishii
Naoki Hasegawa
Norihiro Harada
Tetsuya Ueda
Soichiro Ueda
Takashi Ishiguro
Ken Arimura
Fukuki Saito
Takashi Yoshiyama
Yasushi Nakano
Yoshikazu Mutoh
Yusuke Suzuki
Koji Murakami
Yukinori Okada
Ryuji Koike
Yuko Kitagawa
Akinori Kimura
Seiya Imoto
Satoru Miyano
Seishi Ogawa
Takanori Kanai
Koichi Fukunaga
The Japan COVID-19 Task Force
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07701-y

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.